15h
Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress
Company is winding down global enrollment for the RASolute 302 clinical trial studying daraxonrasib in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback